Protara Therapeutics (TARA) Price & Analysis

Compare

718 Followers

TARA Stock Chart & Stats

Day’s Range― - ―

52-Week Range$1.60 - $10.48

Previous CloseN/A

Volume145.20K

Average Volume (3M)191.23K

Market Cap

$120.38M

Enterprise Value$9.81M

Total Cash (Recent Filing)$122.22M

Total Debt (Recent Filing)$3.95M

Price to Earnings (P/E)―

Beta1.34

Next Earnings

Oct 30, 2025

EPS Estimate

-0.38

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.35

Shares Outstanding38,581,863

10 Day Avg. Volume145,230

30 Day Avg. Volume191,229

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.08

Enterprise Value/Revenue29.56

Enterprise Value/Gross Profit-99.12

Enterprise Value/Ebitda-0.17

Forecast

1Y Price Target

$22.75

Price Target Upside629.17% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

Bulls Say, Bears Say

Bulls Say

Clinical ProgressProtara's TARA-002 has shown similar efficacy and slightly better safety profile compared to BCG in the Phase 2 ADVANCED-2 trial in BCG-Naive NMIBC patients.

Financial StrengthProtara Therapeutics has a strong cash position with approximately $145.6 million in cash, cash equivalents, and investments, which supports its ongoing clinical trials and operations.

Market PotentialThe commercial opportunities are significant, with a multibillion-dollar NMIBC market and thousands of new pediatric LM cases annually.

Bears Say

Clinical Trial DelaysThe interim readout from the Phase 2 ADVANCED-2 study with TARA-002 in Non-Muscle Invasive Bladder Cancer has been pushed back, indicating potential delays in the clinical trial timeline.

Competitor ComparisonModerate-to-high rates of bladder-related toxicity and systemic, flu-like syndrome are notable concerns with BCG treatment.

Regulatory ChallengesThe company just missed the deadline for abstract submission to the SUO 2025, impacting the timing of data presentation.

Protara Therapeutics News

Protara Therapeutics reports Q2 EPS (35c), consensus (38c)

“As we look toward the second half of the year, we believe we are well positioned to continue...

23d ago

TARA

Protara Therapeutics’ IV Choline Chloride: Promising Solution for Liver Dysfunction and Intestinal Failure

Charles Zhu, an analyst from LifeSci Capital, maintained the Buy rating on Protara Therapeutics. The associated price target...

13d ago

TARA

Protara Therapeutics: Strategic Advancements and Promising Outlook Justify Buy Rating

Charles Zhu, an analyst from LifeSci Capital, maintained the Buy rating on Protara Therapeutics. The associated price target...

22d ago

TARA

Protara Therapeutics: Buy Rating Backed by Promising Clinical Advancements and Strategic Focus on Unmet Medical Needs

Andres Y. Maldonado, an analyst from H.C. Wainwright, reiterated the Buy rating on Protara Therapeutics. The associated price...

22d ago

TARA

Protara Therapeutics Reports Q2 2025 Financial Results

Protara Therapeutics, Inc. ( ($TARA) ) has released its Q2 earnings. Here is a breakdown of the information...

22d ago

TARA

Protara Therapeutics, Inc. (TARA) Q2 Earnings Cheat Sheet

Protara Therapeutics, Inc. (TARA) is scheduled to report 2nd quarter earnings on 08/11/2025. Regarding Q2 estimates, Wall Street...

25d ago

TARA

Protara Therapeutics announces addition to Russell 3000 Idex

Protara Therapeutics (TARA) announced that the Company has been added as a member of the broad-market Russell 3000...

2M ago

TARA

Protara Therapeutics Holds Annual Stockholders Meeting

Protara Therapeutics ( ($TARA) ) has issued an update. On June 11, 2025, Protara Therapeutics held its Annual...

3M ago

TARA

Promising Potential of Protara Therapeutics’ TARA-002 in Addressing BCG Shortages for NMIBC Treatment

Soumit Roy, an analyst from JonesTrading, maintained the Buy rating on Protara Therapeutics (TARA – Research Report). The...

3M ago

TARA

Protara appoints William Conkling as Chief Commercial Officer

Protara Therapeutics (TARA) announced the appointment of William “Bill” Conkling as Chief Commercial Officer. He brings more than...

3M ago

TARA

Protara Therapeutics initiated with a Buy at JonesResearch

JonesResearch analyst Soumit Roy initiated coverage of Protara Therapeutics (TARA) with a Buy rating and $21 price target...

3M ago

TARA

Protara Therapeutics Reports Q1 2025 Financial Results

Protara Therapeutics, Inc. ( ($TARA) ) has released its Q1 earnings. Here is a breakdown of the information...

4M ago

TARA

Protara Therapeutics: Buy Rating Affirmed Amid Promising Clinical Data and Strong Financial Position

Charles Zhu, an analyst from LifeSci Capital, maintained the Buy rating on Protara Therapeutics (TARA – Research Report)....

4M ago

TARA

Protara Therapeutics’ TARA-002: A Promising Alternative for NMIBC with Strong Efficacy and Safety Profile

H.C. Wainwright analyst Andres Y. Maldonado has maintained their bullish stance on TARA stock, giving a Buy rating...

4M ago

TARA

TARA FAQ

What was Protara Therapeutics’s price range in the past 12 months?

Protara Therapeutics lowest stock price was $1.59 and its highest was $10.48 in the past 12 months.

What is Protara Therapeutics’s market cap?

Protara Therapeutics’s market cap is $120.38M.

When is Protara Therapeutics’s upcoming earnings report date?

Protara Therapeutics’s upcoming earnings report date is Oct 30, 2025 which is in 57 days.

How were Protara Therapeutics’s earnings last quarter?

Protara Therapeutics released its earnings results on Aug 11, 2025. The company reported -$0.35 earnings per share for the quarter, beating the consensus estimate of -$0.385 by $0.035.

Is Protara Therapeutics overvalued?

According to Wall Street analysts Protara Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Protara Therapeutics pay dividends?

Protara Therapeutics does not currently pay dividends.

What is Protara Therapeutics’s EPS estimate?

Protara Therapeutics’s EPS estimate is -0.38.

How many shares outstanding does Protara Therapeutics have?

Protara Therapeutics has 38,581,863 shares outstanding.

What happened to Protara Therapeutics’s price movement after its last earnings report?

Protara Therapeutics reported an EPS of -$0.35 in its last earnings report, beating expectations of -$0.385. Following the earnings report the stock price went down -0.958%.

Which hedge fund is a major shareholder of Protara Therapeutics?

Currently, no hedge funds are holding shares in TARA

Protara Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-43.02%

Trailing 12-Months

Asset Growth

54.39%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Protara Therapeutics

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.

Protara Therapeutics (TARA) Earnings & Revenues

Historic Earnings Reports

TARA Stock 12 Month Forecast

Average Price Target

$22.75

▲(629.17% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","26":"$26","7.25":"$7.25","13.5":"$13.5","19.75":"$19.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$25.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":22.75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$22.75</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":21,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$21.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,7.25,13.5,19.75,26],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.06,4.747692307692308,6.435384615384615,8.123076923076924,9.810769230769232,11.49846153846154,13.186153846153848,14.873846153846156,16.56153846153846,18.24923076923077,19.936923076923076,21.624615384615385,23.312307692307694,{"y":25,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.06,4.5746153846153845,6.0892307692307694,7.603846153846154,9.118461538461538,10.633076923076924,12.147692307692308,13.662307692307694,15.176923076923078,16.69153846153846,18.206153846153846,19.720769230769232,21.235384615384614,{"y":22.75,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.06,4.44,5.82,7.200000000000001,8.58,9.96,11.340000000000002,12.72,14.100000000000001,15.480000000000002,16.86,18.240000000000002,19.62,{"y":21,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4.14,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.93,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.11,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.47,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.53,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.28,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.92,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.74,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.01,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.46,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.3,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.06,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >